Atrion traded at $441.74 this Tuesday April 9th, increasing $24.97 or 5.99 percent since the previous trading session. Looking back, over the last four weeks, Atrion gained 1.41 percent. Over the last 12 months, its price fell by 32.14 percent. Looking ahead, we forecast Atrion to be priced at 428.40 by the end of this quarter and at 390.75 in one year, according to Trading Economics global macro models projections and analysts expectations.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products primarily for medical applications. The Company markets components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. Its medical products primarily serve the fluid delivery, cardiovascular and ophthalmology markets. Its fluid delivery products include valves designed to fill, hold and release controlled amounts of fluids or gasses in fields, such as anesthesia and oncology. Its cardiovascular product, Myocardial Protection System (MPS3), is a technology used in the open-heart surgery that delivers fluids and medications, mixes critical drugs, and controls temperature and pressure. Its ophthalmic products include specialized medical devices that disinfect contact lenses. Atrion also manufacture a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.